JP2011522816A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522816A5
JP2011522816A5 JP2011512416A JP2011512416A JP2011522816A5 JP 2011522816 A5 JP2011522816 A5 JP 2011522816A5 JP 2011512416 A JP2011512416 A JP 2011512416A JP 2011512416 A JP2011512416 A JP 2011512416A JP 2011522816 A5 JP2011522816 A5 JP 2011522816A5
Authority
JP
Japan
Prior art keywords
symptoms
compound
schizophrenia
anxiety
delaying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011512416A
Other languages
English (en)
Japanese (ja)
Other versions
JP5476371B2 (ja
JP2011522816A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2009/050682 external-priority patent/WO2009148403A1/en
Publication of JP2011522816A publication Critical patent/JP2011522816A/ja
Publication of JP2011522816A5 publication Critical patent/JP2011522816A5/ja
Application granted granted Critical
Publication of JP5476371B2 publication Critical patent/JP5476371B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011512416A 2008-06-06 2009-06-08 イソオキサゾール誘導体及び代謝型グルタミン酸受容体ポテンシエーターとしてのその使用 Expired - Fee Related JP5476371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5948508P 2008-06-06 2008-06-06
US61/059,485 2008-06-06
PCT/SE2009/050682 WO2009148403A1 (en) 2008-06-06 2009-06-08 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014020956A Division JP5815765B2 (ja) 2008-06-06 2014-02-06 イソオキサゾール誘導体及び代謝型グルタミン酸受容体ポテンシエーターとしてのその使用

Publications (3)

Publication Number Publication Date
JP2011522816A JP2011522816A (ja) 2011-08-04
JP2011522816A5 true JP2011522816A5 (enExample) 2012-07-19
JP5476371B2 JP5476371B2 (ja) 2014-04-23

Family

ID=41398335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011512416A Expired - Fee Related JP5476371B2 (ja) 2008-06-06 2009-06-08 イソオキサゾール誘導体及び代謝型グルタミン酸受容体ポテンシエーターとしてのその使用
JP2014020956A Expired - Fee Related JP5815765B2 (ja) 2008-06-06 2014-02-06 イソオキサゾール誘導体及び代謝型グルタミン酸受容体ポテンシエーターとしてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014020956A Expired - Fee Related JP5815765B2 (ja) 2008-06-06 2014-02-06 イソオキサゾール誘導体及び代謝型グルタミン酸受容体ポテンシエーターとしてのその使用

Country Status (40)

Country Link
US (4) US7790760B2 (enExample)
EP (2) EP2303872B1 (enExample)
JP (2) JP5476371B2 (enExample)
KR (1) KR20110020797A (enExample)
CN (1) CN102105466B (enExample)
AR (1) AR072016A1 (enExample)
AU (1) AU2009255784B2 (enExample)
BR (1) BRPI0913585A2 (enExample)
CA (1) CA2726925A1 (enExample)
CL (1) CL2010001348A1 (enExample)
CO (1) CO6321239A2 (enExample)
CR (1) CR11826A (enExample)
CU (1) CU23883B1 (enExample)
CY (1) CY1115301T1 (enExample)
DK (1) DK2303872T3 (enExample)
DO (1) DOP2010000375A (enExample)
EA (2) EA018412B1 (enExample)
EC (1) ECSP10010662A (enExample)
ES (1) ES2469837T3 (enExample)
GT (1) GT201000342A (enExample)
HK (1) HK1201255A1 (enExample)
HN (1) HN2010002582A (enExample)
HR (1) HRP20140451T1 (enExample)
IL (1) IL209622A0 (enExample)
MX (1) MX2010012949A (enExample)
MY (1) MY156552A (enExample)
NI (3) NI201000209A (enExample)
NZ (1) NZ590344A (enExample)
PE (1) PE20110028A1 (enExample)
PL (1) PL2303872T3 (enExample)
PT (1) PT2303872E (enExample)
RS (1) RS53392B (enExample)
SA (1) SA109300358B1 (enExample)
SI (1) SI2303872T1 (enExample)
SV (1) SV2010003751A (enExample)
TW (3) TW201514173A (enExample)
UA (1) UA107649C2 (enExample)
UY (1) UY31870A (enExample)
WO (1) WO2009148403A1 (enExample)
ZA (1) ZA201008611B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
MX2010002536A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas.
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2409006T3 (es) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
EA202192105A3 (ru) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
US10099993B2 (en) 2014-04-06 2018-10-16 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
KR101663662B1 (ko) * 2015-06-17 2016-10-14 한국과학기술연구원 대사성 글루타메이트 수용체 1에 활성을 지닌 신규 아릴 아이소옥사졸 유도체
US20170145002A1 (en) * 2015-11-25 2017-05-25 Astrazeneca Ab Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3993617A (en) 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
EP0999208A4 (en) 1997-05-30 2001-08-08 Meiji Seika Kaisha NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
ATE366249T1 (de) 2000-02-29 2007-07-15 Mitsubishi Pharma Corp Zyklische amid-derivate
CN1444573A (zh) 2000-07-31 2003-09-24 史密丝克莱恩比彻姆有限公司 甲酰胺化合物及其作为人11cby受体拮抗剂的用途
PL368129A1 (en) 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
JP2006521358A (ja) 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体のベンズアミドモジュレータ
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
CA2542220A1 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
EP1713775A4 (en) 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
MY152888A (en) 2004-02-18 2014-11-28 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
CN102558082B (zh) 2004-03-05 2015-09-30 日产化学工业株式会社 异噁唑啉取代苯甲酰胺化合物的制备中间体
CN1934094A (zh) 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CN101048157A (zh) 2004-10-25 2007-10-03 默克公司 代谢型谷氨酸受体的杂环二氢茚酮增强剂
WO2006091496A2 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
JP2008540635A (ja) 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
JP5031745B2 (ja) * 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون

Similar Documents

Publication Publication Date Title
JP2011522816A5 (enExample)
JP2010529118A5 (enExample)
JP2013525444A5 (enExample)
JP2013516442A5 (enExample)
JP2010536849A5 (enExample)
JP2012532874A5 (enExample)
JP2014521735A5 (enExample)
JP2012520866A5 (enExample)
JP2012515720A5 (enExample)
JP2010528011A5 (enExample)
JP2006143751A5 (enExample)
JP2008539268A5 (enExample)
HRP20180942T1 (hr) Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima
JP2012502037A5 (enExample)
JP2015537009A5 (enExample)
EP3276004A3 (en) Methods for treating chronic kidney disease
JP2010518061A5 (enExample)
JP2014503593A5 (enExample)
JP2009537554A5 (enExample)
JP2016512817A5 (enExample)
JP2013541583A5 (enExample)
JP2009538898A5 (enExample)
JP2012508256A5 (enExample)
JP2021073257A5 (enExample)
JP2009517411A5 (enExample)